CRAF is a crucial mediator of resistance to RAF/MEK inhibition in BRAF-mutant melanoma and colorectal cancer models (Montagut et al. 2008; Whittaker et al. 2015), through sustained ERK pathway activation. Here, RAF1 is linked to colorectal cancer.